Data Insights

Feladilimab by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Squamous Non-Small Cell Lung Cancer

Data Insights

Feladilimab by GSK for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

Feladilimab by GSK for Non-Small Cell Lung Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Non-Small Cell Lung Cancer

Data Insights

Feladilimab by GSK for Hypopharyngeal Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Hypopharyngeal Cancer

Data Insights

Feladilimab by GSK for Laryngeal Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Laryngeal Cancer

Data Insights

Feladilimab by GSK for Oropharyngeal Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Oropharyngeal Cancer

Data Insights

Feladilimab by GSK for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Oral Cavity (Mouth) Cancer

Data Insights

Feladilimab by GSK for Cervical Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Cervical Cancer

Data Insights

Feladilimab by GSK for Bladder Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Bladder Cancer

Data Insights

Feladilimab by GSK for Malignant Pleural Mesothelioma: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Malignant Pleural Mesothelioma

Data Insights

Feladilimab by GSK for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Human Papillomavirus (HPV) Associated Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Human Papillomavirus (HPV) Associated Cancer

Data Insights

Feladilimab by GSK for Metastatic Colorectal Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Metastatic Colorectal Cancer

Data Insights

Feladilimab by GSK for Metastatic Prostate Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Metastatic Prostate Cancer

Data Insights

Feladilimab by GSK for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Paranasal Sinus And Nasal Cavity Cancer

Data Insights

Feladilimab by GSK for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Feladilimab by GSK for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Feladilimab by GSK for Metastatic Melanoma: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Metastatic Melanoma

Data Insights

Feladilimab by GSK for Solid Tumor: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Solid Tumor

Data Insights

Feladilimab by GSK for Renal Cell Carcinoma: Likelihood of Approval

Feladilimab is under clinical development by GSK and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Renal Cell Carcinoma